Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy
Overview
Oncology
Authors
Affiliations
Objective: The study aims to identify preoperative predictors of complete cytoreduction and early recurrence and death in epithelial ovarian, tubal, and peritoneal cancer after neoadjuvant chemotherapy (NACT).
Methods: We performed a retrospective analysis of 85 patients who underwent 3 cycles of NACT. Patients were divided into 2 groups according to residual tumor at interval debulking surgery (IDS), and clinicopathologic, surgical, and follow-up data were compared.
Results: Cancer antigen 125 (CA-125) levels before the IDS after completion of NACT were higher in the residual tumor group (42.0 vs 116.6 U/mL, P = 0.006). The drop rate of CA-125 after NACT was higher in the no residual tumor group (96.8% vs 89.9%, P = 0.001). Patients with residual tumor showed lower disease-free and overall survival outcomes than patients with no residual tumor. In univariate analysis, CA-125 of 100 U/mL or less before IDS and a drop rate after NACT greater than 80% were preoperative predictive factors for complete cytoreduction. In multivariate analysis, a drop rate of CA-125 after NACT greater than 80% was an independent preoperative predictive factor for complete cytoreduction (P = 0.002). Progressive disease on follow-up image during NACT was an independent preoperative predictive factor for early recurrence and death (P < 0.001, both).
Conclusions: A significant drop of CA-125 after NACT and progressive disease on follow-up image are independent preoperative predictors for complete cytoreduction and early recurrence and death.
Oufkir N, Rouzier R, Paoletti X, Bonneau C J Ovarian Res. 2024; 17(1):152.
PMID: 39039554 PMC: 11265035. DOI: 10.1186/s13048-024-01476-3.
Theodoulidis V, Prodromidou A, Stamatakis E, Alexakis N, Rodolakis A, Haidopoulos D Mol Clin Oncol. 2022; 17(1):113.
PMID: 35747592 PMC: 9204212. DOI: 10.3892/mco.2022.2546.
Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer.
Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood A, Fleming N Cancers (Basel). 2021; 13(4).
PMID: 33562443 PMC: 7915369. DOI: 10.3390/cancers13040626.
Inflammatory signals induce MUC16 expression in ovarian cancer cells via NF-κB activation.
Liu J, Li L, Luo N, Liu Q, Liu L, Chen D Exp Ther Med. 2021; 21(2):163.
PMID: 33456530 PMC: 7792485. DOI: 10.3892/etm.2020.9594.
Feng L, Liao S, Li L J Ovarian Res. 2020; 13(1):17.
PMID: 32050995 PMC: 7014747. DOI: 10.1186/s13048-020-0614-1.